All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treating classical Hodgkin lymphoma: Spotlight on targeted therapies

with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce

Saturday, November 2, 2024
8:50-9:50 CET

Register now

This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2018-12-07T15:42:56.000Z

EMA grants approval to mogamulizumab for patients with previously treated cutaneous T-cell lymphoma

Dec 7, 2018
Share:

On 26 November 2018, mogamulizumab, a humanized monoclonal antibody directed against the CC chemokine receptor 4 (CCR4), received marketing authorization from the European Medicines Agency (EMA) for the treatment of adult patients with previously treated cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) or Sézary syndrome (SS), who have received at least one prior systemic therapy.

The approval granted by the EMA was based on positive results from the international, open-label, randomized, controlled, phase III MAVORIC trial (NCT01728805) comparing mogamulizumab with vorinostat in patients with previously treated MF and SS. Mogamulizumab therapy resulted in superior investigator-assessed progression-free survival in the intent-to-treat population compared with vorinostat therapy (median 7.7 months [95% CI, 5.7–10.3] versus 3.1 months [95% CI, 2.9–4.1] respectively, P < 0.0001).

The phase III trial investigators concluded that mogamulizumab could provide a new, effective treatment for patients with MF and, importantly, for SS, a subtype that represents a major therapeutic challenge in CTCL.

  1. Kyowa Hakko Kirin: Kyowa Kirin announces POTELIGEO® receives marketing authorisation in Europe for the treatment of Mycosis Fungoides and Sézary Syndrome. 2018 Nov 26. https://www.kyowa-kirin.com/news_releases/2018/e20181126_01.html. [Accessed 2018 Dec 7].
  2. Kim Y. H. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled, phase 3 trial. Lancet. 2018 Aug 9; 19(9): 1192–1204. DOI:https://doi.org/10.1016/S1470-2045(18)30379-6.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox